Analysis of neglected tropical disease drug and vaccine development pipelines to predict issuance of FDA priority review vouchers over the next decade.
Rianna Stefanakis, Andrew S Robertson, Elizabeth L Ponder, Melinda Moree
Author Information
- Rianna Stefanakis: BIO Ventures for Global Health, San Francisco, California, United States of America. rstefanakis@bvgh.org
No abstract text available.
- Lancet. 2002 Jun 22;359(9324):2188-94
[PMID: 12090998]
- Nat Rev Drug Discov. 2004 Aug;3(8):711-5
[PMID: 15286737]
- PLoS Negl Trop Dis. 2012;6(8):e1750
[PMID: 22953004]
- Nat Biotechnol. 1996 May;14(5):591-3
[PMID: 9630948]
- N Engl J Med. 2007 Sep 6;357(10):1018-27
[PMID: 17804846]
- J Health Econ. 2003 Mar;22(2):151-85
[PMID: 12606142]
- Health Aff (Millwood). 2006 Mar-Apr;25(2):313-24
[PMID: 16522573]
- Lancet. 2006 May 13;367(9522):1560-1
[PMID: 16698397]
- Clin Pharmacol Ther. 2001 May;69(5):286-96
[PMID: 11371996]
- Health Econ. 2010 Feb;19(2):130-41
[PMID: 19247981]
- Science. 2006 Mar 3;311(5765):1246-7
[PMID: 16513969]
Communicable Diseases
Drug Approval
Drug Discovery
Humans
Neglected Diseases
Tropical Medicine
United States
United States Food and Drug Administration
Vaccines
